Abstract
Introduction
Serous cystadenocarcinoma (SCAc) of the pancreas is the rare malignant counterpart of serous cystadenoma, with fewer than 40 reported cases. Its clinical behavior and optimal management remain poorly defined. This systematic review summarizes the presentation, diagnosis, treatment, and outcomes of pancreatic SCAc.
Methods
A systematic search of PubMed, Scopus, Web of Science, and Embase was performed from inception through December 2025. Thirty-six studies describing 38 histologically confirmed cases met inclusion criteria. Data on demographics, tumor characteristics, imaging, management, and outcomes were extracted and summarized descriptively.
Results
Median age at diagnosis was 66.5 years (IQR 55.8-71.0), and 71% of patients were female. Abdominal pain and incidental imaging findings were the most common presentations. Tumors were typically large and located in the pancreatic body or tail. Local invasion occurred in 74% of cases. Distant metastases were present in 68% (26 of 38), most commonly to the liver. All patients underwent surgical resection. Chemotherapy use was rare. Recurrence was reported in 26% of cases, with a median disease-free interval of roughly 50 months. Disease-related mortality was infrequently reported.
Conclusions
Despite frequent invasion and metastasis, SCAc often demonstrates an indolent course, and long-term survival is common after resection. Surgical management remains central to treatment. Given its rarity and diagnostic limitations, individualized management and prolonged surveillance are warranted.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
